Results 51 to 60 of about 65,460 (210)

Adult-onset mastocytosis in the skin is highly suggestive of systemic mastocytosis

open access: yes, 2014
Adult-onset urticaria pigmentosa/mastocytosis in the skin almost always persists throughout life. The prevalence of systemic mastocytosis in such patients is not precisely known. Bone marrow biopsies from 59 patients with mastocytosis in the skin and all
Flaig, Michael J.   +9 more
core   +1 more source

Characterization of CD123 expression by mast cells in systemic mastocytosis with multicolor flow cytometry

open access: yesCytometry Part B: Clinical Cytometry, EarlyView.
Abstract Systemic mastocytosis (SM) is a clonal mast cell (MC) disorder characterized by aberrant immunophenotypes, including expression of CD25, CD2, and occasionally CD30. CD123, the α‐subunit of the interleukin‐3 receptor, is a therapeutic target in hematologic malignancies and has been reported to be expressed on neoplastic MCs by ...
Ryan C. Shean   +2 more
wiley   +1 more source

Sequence of Immunological Events During IgE‐Mediated Allergic Reactions to Food

open access: yesAllergy, EarlyView.
ABSTRACT Food allergies (FA) represent a significant global health burden. Upon allergen re‐exposure, allergic patients exhibit a sequence of symptoms that vary in terms of affected organ systems, severity, time of onset and allergen reactivity thresholds.
N. A. Nagy   +7 more
wiley   +1 more source

Gastrointestinal tract involvement in systemic mastocytosis: a clinical case

open access: yesPatologìâ
Mastocytosis is a group of rare heterogeneous diseases caused by excessive proliferation and accumulation of mast cells in various organs and systems.
Ya. S. Bereznytskyi   +5 more
doaj   +1 more source

Cutaneous and Gastrointestinal Symptoms in Two Patients with Systemic Mastocytosis Successfully Treated with Omalizumab

open access: yesCase Reports in Medicine, 2015
The pathogenesis of mastocytosis is not well defined and thus treatment remains challenging and remains on a palliative basis. We present two cases (a 48-year-old woman and a 57-year-old man) with indolent systemic mastocytosis in whom omalizumab (anti ...
Sofie Lieberoth, Simon Francis Thomsen
doaj   +1 more source

The International Guideline for the Definition, Classification, Diagnosis and Management of Urticaria

open access: yesAllergy, EarlyView.
ABSTRACT This update and revision of the international guideline for urticaria was developed in accordance with the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. It is an initiative of the Global Allergy and Asthma Excellence Network (GA2LEN) and its Urticaria and ...
T. Zuberbier   +221 more
wiley   +1 more source

Bullous mastocytosis: a Case Report

open access: yesJournal of the Egyptian Women’s Dermatologic Society
Mastocytosis is a disorder characterized by abnormal mast cell proliferation. The skin is the most common site of involvement. Extracutaneous involvement occurs in systemic mastocytosis with infiltrations in the gastrointestinal tract, lymph nodes, bone ...
Galal El Enany   +7 more
doaj   +1 more source

Hypotension, Syncope, and Fever in Systemic Mastocytosis without Skin Infiltration and Rapid Response to Corticosteroid and Cyclosporin: A Case Report

open access: yesCase Reports in Medicine, 2010
Mast cell disorders are defined by an abnormal accumulation of tissue mast cells in one or more organ systems. In systemic mastocytosis, at least one extracutaneous organ is involved by definition.
Didem Ozdemir   +6 more
doaj   +1 more source

Venom immunotherapy in indolent systemic mastocytosis with high serum tryptase level

open access: yesHuman Vaccines & Immunotherapeutics, 2021
Mastocytosis is a rare group of disorders characterized by abnormal accumulation of mast cells in the skin, bone marrow, and internal organs. In particular, patients with systemic mastocytosis are at an increased risk of frequent and severe episodes of ...
Ali Selcuk, Abdullah Baysan
doaj   +1 more source

Safety of Venom Immunotherapy in Pregnancy: A Multicentre Study

open access: yesAllergy, EarlyView.
Venom immunotherapy (VIT) during pregnancy, when maintenance dose is well tolerated, can be continued. No increased risk of adverse effects to VIT or safety concerns for the pregnancy or the newborns were observed. No decreased efficacy of VIT, in case of re‐stings, was reported.
Matteo Martini   +20 more
wiley   +1 more source

Home - About - Disclaimer - Privacy